Glenmede Trust’s Avadel Pharmaceuticals AVDL Stock Holding History

Glenmede Trust’s Portfolio AVDL Stock Details AVDL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q4	–	Sell	-31	Closed	–	–	2650
2015 Q3	$0	Hold	31	–	–	﹤0.01%	2711
2015 Q2	$0	Buy	+31	New	+$556	﹤0.01%	2683

Other funds holding AVDL

Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return

JHIU

Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

PCM

Portolan Capital Management Boston, Massachusetts $1.88B AUM 115.74% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

FPC

Falcon Point Capital San Francisco, California $11.9M AUM 55.76% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

JGC

J. Goldman & Co New York $3.44B AUM 33.8% 1-Year Est. Return

Glenmede Trust's AVDL Position: Q4 2015 in Review

Glenmede Trust sold out of Avadel Pharmaceuticals (AVDL) in Q4 2015, closing a stake of 31 shares.

Glenmede Trust first reported a position in AVDL in Q2 2015 and held it in 2 quarters. The position peaked at $0 in Q3 2015. 89 funds tracked by Wall St. Rank hold AVDL as of Q4 2015.

Glenmede Trust reported no remaining Avadel Pharmaceuticals position as of Q4 2015 after selling out during the quarter.
Glenmede Trust sold 31 Avadel Pharmaceuticals shares in Q4 2015.
Glenmede Trust first reported a position in Avadel Pharmaceuticals in Q2 2015 and held it in 2 quarters.
Glenmede Trust's Avadel Pharmaceuticals position peaked at $0 in Q3 2015.
89 funds tracked by Wall St. Rank held Avadel Pharmaceuticals as of Q4 2015.

Based on Glenmede Trust's 13F filing for Q4 2015, filed 11 Feb 2016.